CGRP Antagonist Compounds for Migraine Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions such as migraines, cluster headaches, and other inflammatory and pain-related disorders lack effective and side-effect-minimized options, particularly for acute and prophylactic management.
Innovation Solution
Development of CGRP antagonists in the form of specific compounds with the general formula I, which include various substituents and their physiologically tolerated salts, demonstrating affinity for CGRP receptors and antagonistic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for migraines and inflammatory disorders are used, then therapeutic effect is achieved, but side effects increase
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with modified molecular structures (formula I with specific substituents U, V, X, Y, R1, R4) to achieve selective CGRP receptor antagonism. This structural parameter optimization allows the compound to selectively bind to CGRP receptors while minimizing interactions with other targets, thereby reducing side effects while maintaining therapeutic efficacy for migraines and inflammatory disorders
2Reliability
If effective treatments for acute and prophylactic management are developed, then therapeutic efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of CGRP (calcitonin gene-related peptide) overactivity in migraines and inflammatory disorders. By developing compounds that selectively antagonize CGRP receptors rather than using broad-spectrum analgesics or anti-inflammatories, the treatment addresses the root cause with specificity. This mechanism-based approach simplifies treatment strategy by focusing on a single validated target pathway, reducing the need for complex combination therapies
Data Source
AI summary
The invention relates to novel CGRP antagonists of general formula (I) in which U, V, X, Y, R1, R2, R3, and R4 are defined as indicated in the description, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures, and salts thereof, and the hydrates of the salts, especially the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing said compounds, the use thereof, and methods for the production thereof.